Model-Integrated Evidence (MIE) is increasingly becoming an important component of science-driven generic drug development. By integrating quantitative modeling and simulation with available in vitro and in vivo evidence, MIE provides a framework for addressing complex questions related to bioequivalence (BE), product performance, and regulatory decision-making.
The importance of such approaches is particularly evident for complex drug products, where conventional pharmacokinetic or comparative clinical approaches may be difficult, insensitive, or resource intensive. Quantitative approaches such as physiologically based pharmacokinetic (PBPK) modeling, population pharmacokinetic (PopPK) modeling, and other mechanistic modeling strategies can complement experimental evidence and strengthen the overall assessment of BE.
In October 2023, the FDA launched the Model-Integrated Evidence (MIE) Industry Meeting Pilot Program to facilitate early scientific interactions with generic drug applicants proposing MIE approaches for bioequivalence (BE) assessment. The initiative is particularly relevant for complex and challenging drug products, such as long-acting injectables and topically applied dermatological products, for which conventional PK or comparative clinical approaches may be challenging or may not adequately characterize product performance. Importantly, the scope of MIE extends beyond virtual BE and can include different quantitative modeling approaches depending on the product, available evidence, and regulatory question.
From modeling approaches to regulatory implementation
One of the key opportunities offered by the MIE framework is the integration of multiple sources of evidence rather than considering modeling as an isolated component. A well-developed and adequately verified model can beevaluated alongside formulation characteristics, in vitro performance, clinical pharmacokinetics, and other available evidence to address specific regulatory questions.
For generic drug developers, early consideration of MIE may help identify critical knowledge gaps, inform formulation and study design, evaluate sources of variability, and assess whether alternative BE strategies are scientifically justified. Importantly, the value of MIE depends not only on model development but also on appropriate model verification, validation, documentation, and demonstration of fitness for the intended regulatory purpose.
What can we learn from FDA’s upcoming MIE workshop?
FDA’s upcoming virtual workshop, “Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs,” scheduled for August 27, 2026, providesan important opportunity to understand how this rapidly evolving field is being translated into regulatory practice.
A key focus of the workshop will be an overview of MIE submissions received by the FDA and the key learnings emerging from these submissions. The workshop will also address current regulatory expectations and lessons learned for PopPK modeling, locally acting PBPK modeling, and oral PBPK modeling in generic drug submissions. Discussions on practical implementation, common pitfalls, and case studies can provide valuable insights into how these approaches can be effectively incorporated into generic drug development programs.
The workshop will also highlight the broader role of MIE in shaping FDA product-specific and general guidance development across a range of drug products, including orally inhaled drug products, long-acting injectables, ophthalmic drug products, and oral drug products. These discussions and case examples can provide practical insight into how in vitro, in vivo, and in silico evidence can be integrated to address product-specific challenges and support BE assessment and regulatory decision-making.
Another important topic will be ICH M15, “General Principles for Model-Informed Drug Development,” which reached Step 4 in January 2026 and has now progressed to Step 5 for regulatory implementation. This milestone supports global harmonization and may encourage broader adoption of model-informed and in silico approaches across rest-of-world (ROW) markets.
Altogether, these discussions can help researchers, modelers, sponsors, and generic drug applicants better understand where MIE can add value, what regulators expect from model-informed submissions, and how quantitative evidence can be translated into regulatory-grade evidence. Such understanding may enable more informed development strategies, help minimize avoidable development and regulatory iterations, and support the broader implementation of MIE in generic drug development. Ultimately, the effective integration of modeling with in vitro and in vivo evidence can contribute to more efficient, science-driven, and cost-effective development of high-quality generic drug products.
